Shots:

• The approval is based on P-II CodeBreaK 100 trial evaluating the efficacy and tolerability of Lumakras (PO- qd) in 126 patients with KRAS G12C mutation-positive advanced NSCLC whose disease had progressed after prior treatment with immunotherapy or CT
• The 1EPs were centrally assessed ORR. Additionally- the therapy demonstrated a positive benefit-risk profile with rapid- deep- and durable anticancer activity
• The therapy is also being studied in multiple other solid tumors. The company has completed enrollment in the P-III CodeBreaK 200 study for sotorasib vs docetaxel in patients with the same indication & results of the P-II trial in CRC is expected in later 2021

  | Ref: Newswire Canada | Image: BioSpace